Department of Dermatology, Vrije Universeit Medical Center Amsterdam, Amsterdam, The Netherlands.
Department of Epidemiology and Biostatistics, Amsterdam Public Health Research Institute, VU University Medical Center, Amsterdam, The Netherlands.
J Eur Acad Dermatol Venereol. 2018 Sep;32(9):1476-1484. doi: 10.1111/jdv.14850. Epub 2018 Mar 30.
Lentigo maligna (LM), a form of melanoma in situ, is treated to prevent progression to lentigo maligna melanoma (LMM). Surgical treatment is the gold standard. However, treatment guidelines are based on expert opinion, and comparative studies are lacking.
The objective of this study was to assess the diagnostic methods and clinical management of LM patients among European dermatologists and residents.
A survey consisting of 29 questions about diagnostic methods and treatment options used for LM patients was sent to 3308 members of the European Association of Dermatologists and Venereologists (EADV).
Most questions were multiple choice, and multiple answers could be ticked per question. A total of N = 415 (12.5%) completed surveys were included in the analyses. A combination of clinical diagnosis (65.7%), dermatoscopy (83.4%) and histopathology (88.2%) is used by most respondents to diagnose LM. Tissue for histopathological evaluation was collected most often using a single punch biopsy in 61.0%. The most common treatment for LM patients <60 years of age is surgery (97.6%). For LM patients >70 years of age, 66.8% of the respondents preferred surgical treatment. Non-surgical options such as radiotherapy (17.0%), topical imiquimod (30.6%), watchful waiting (19.6%) or cryotherapy (20.4%) were used in this elderly group. Subanalysis showed that respondents who take into account patient preference used topical imiquimod, radiotherapy and watchful waiting more often.
In conclusion, the results of this survey show that there is a variance in the diagnostic methods and treatment modalities used for LM across Europe. Surgery remains the most utilized option. However, non-surgical options, such as topical imiquimod and radiotherapy, are most often used for elderly patients. We recommend that future studies focus on patient preference and compare surgical to non-surgical therapy.
原位性恶性雀斑样痣(LM)是一种黑色素瘤,其治疗目的是防止进展为恶性雀斑样黑素瘤(LMM)。手术治疗是金标准。然而,治疗指南是基于专家意见制定的,缺乏比较研究。
本研究旨在评估欧洲皮肤科医生和住院医师对 LM 患者的诊断方法和临床管理。
向欧洲皮肤病学会和性病学会(EADV)的 3308 名成员发送了一份包含 29 个关于 LM 患者诊断方法和治疗选择问题的调查。
大多数问题都是多项选择题,每个问题可以勾选多个答案。共纳入了 415 份(12.5%)完成的调查进行分析。大多数受访者使用临床诊断(65.7%)、皮肤镜检查(83.4%)和组织病理学(88.2%)相结合来诊断 LM。用于组织病理学评估的组织最常通过单次活检采集,占 61.0%。对于<60 岁的 LM 患者,最常见的治疗方法是手术(97.6%)。对于>70 岁的 LM 患者,66.8%的受访者首选手术治疗。在这个老年组中,非手术选择如放疗(17.0%)、局部咪喹莫特(30.6%)、观察等待(19.6%)或冷冻疗法(20.4%)也被使用。亚组分析表明,考虑患者意愿的受访者更常使用局部咪喹莫特、放疗和观察等待。
总之,这项调查的结果表明,欧洲各地用于 LM 的诊断方法和治疗方式存在差异。手术仍然是最常用的选择。然而,对于老年患者,非手术选择如局部咪喹莫特和放疗最常被使用。我们建议未来的研究侧重于患者的偏好,并比较手术和非手术治疗。